Roughly how many patients do you treat with Narcolepsy?

Do you currently prescribe LUMRYZ?

Have many patients come proactively to you to speak about LUMRYZ, or do you only talk about it when you bring it up to them?

When you see Xyrem/Xywav patients on their regular schedule follow-up visits, are you bringing up Lumryz to them?  If so, what % of Xyrem/Xywav patients that you discuss Lumryz with have expressed a strong interest in switching?

What % of patients who were on Xyrem/Xywav prior to Lumryz's launch do you expect to switch to LUMRYZ over the next year?  For those who aren't going to switch over the next year, do you think a good chunk will switch later or if they don't switch within a year's time they will probably never switch?  And for the patients who aren't switching to LUMRYZ, what are the main reasons they are deciding to stay on Xyrem/Xywav?

What % of your new Oxybate starts are choosing Lumryz vs. Xyrem/Xywav?  For the patients who are choosing Xyrem/Xywav, what are the main reasons for choosing that over Lumryz?

How concerned are you about the higher sodium level of Lumryz vs. Xywav and is this issue playing a big role in limiting the number of switches to Lumryz and/or favoring Xywav for new starrts?   How concerned are patients about the sodium issue and do you see the decision of once nightly vs. low sodium to be a tough tradeoff or not?

How many patients do you have on Oxybate today, including Lumryz, Xyrem, Generic Xyrem, and Xywav?  How many patients have you sent to the RYZUP program to get Lumryz since the drug launched to today (a period of roughly 2.5 months)?  Compared to the number of patients taht you sent to RYZUP over the last 2.5 months, how many do you expect to send to RYZUP over the next 2.5 months.... will the number be similar, or will it move up as kinks get worked out and familiarity with the drug increases?

Of the patients that you have sent to RYZUP, what % of those do you think will ultimately end up on LUMRYZ with coverage from insurance and what % will drop off due to either non-coverage or just not following through?

How has your experience been prescribing LUMRYZ so far?  Does it take a lot of work to get it approved by insurance, or generally pretty easy?  

Avadel points to two potential pockets of market expansion for Lumryz: 1) patients who previously tried oxybate therapy but dropped off with the 2x dosing regimen being an issue, and 2) patients who were suggested to try oxybate therapy but didn't in part because the 2x dosing regimen was too cumbersome or undesirable for them.  How much of an opportunity for market expansion do you see with these populations?